Glycolytic activity and in vitro effect of the pyruvate kinase activator AG-946 in red blood cells from low-risk myelodysplastic syndromes patients: A proof-of-concept study

Am J Hematol. 2024 Jun;99(6):1201-1204. doi: 10.1002/ajh.27300. Epub 2024 Apr 2.

Abstract

Glycolytic activity and in vitro effect of the pyruvate kinase activator AG-946 in red blood cells from low-risk myelodysplastic syndromes patients. Data showed decreased glycolytic activity in red blood cells of 2/3 of patients with lower-risk MDS. These results highlight a potential effect of the PK activator in this setting.

Publication types

  • Letter

MeSH terms

  • Aged
  • Aged, 80 and over
  • Erythrocytes* / drug effects
  • Erythrocytes* / metabolism
  • Female
  • Glycolysis* / drug effects
  • Humans
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes* / blood
  • Myelodysplastic Syndromes* / drug therapy
  • Proof of Concept Study
  • Pyruvate Kinase*